- Home
- NRIX vs SPNT Comparison
NRIX vs SPNT Comparison
Compare NRIX & SPNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NRIX | SPNT |
|---|---|---|
| Founded | 2009 | 2011 |
| Country | United States | Bermuda |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.8B |
| IPO Year | 2020 | 2013 |
Fundamental Metrics
Financial Performance| Metric | NRIX | SPNT |
|---|---|---|
| Price | $25.37 | $25.76 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 5 |
| Target Price | ★ $34.50 | $28.75 |
| AVG Volume (30 Days) | ★ 1.9M | 707.5K |
| Earning Date | 10-12-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 250.00 |
| EPS | ★ 3.26 | 1.40 |
| Revenue | $76,987,000.00 | ★ $3,205,100,000.00 |
| Revenue This Year | $786.93 | $3.57 |
| Revenue Next Year | N/A | $5.58 |
| P/E Ratio | ★ $7.82 | $18.46 |
| Revenue Growth | ★ 99.31 | 23.09 |
| 52 Week Low | $11.19 | $17.71 |
| 52 Week High | $28.23 | $26.50 |
Technical Indicators
Market Signals| Indicator | NRIX | SPNT |
|---|---|---|
| Relative Strength Index (RSI) | 58.20 | 60.25 |
| Support Level | $24.61 | $22.22 |
| Resistance Level | $28.23 | $26.30 |
| Average True Range (ATR) | 1.21 | 0.60 |
| MACD | 0.39 | 0.07 |
| Stochastic Oscillator | 81.41 | 76.04 |
Price Performance
Historical ComparisonAbout NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
About SPNT SiriusPoint Ltd.
SiriusPoint Ltd provides property and casualty reinsurance coverage to insurance and reinsurance companies in the United States, Canada, Bermuda, the United Kingdom, and Europe. The company operates through two operating segments: Reinsurance and Insurance & Services. The company's product portfolio consists of reinsurance contracts for property insurance including both residential and commercial properties, workers' compensation, personal automobile, businesses' general liability insurance, professional liability insurance to protect professional advisors and service providers, agriculture insurance, and mortgage insurance. The majority of the revenue is generated from its Insurance & Services segment.